Stoke Therapeutics (STOK) Other Non-Current Liabilities (2021 - 2026)
Stoke Therapeutics (STOK) posted quarterly Other Non-Current Liabilities of $991000.0 for Q1 2026, down 47.12% year-over-year from $1.9 million in Q1 2025, and down 13.15% quarter-over-quarter from $1.1 million in Q4 2025.
Stoke Therapeutics (STOK) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Stoke Therapeutics' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $991000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 47.12% year-over-year to $991000.0; the TTM figure through Mar 2026 stood at $991000.0 (down 47.12% YoY), while the FY2025 annual figure was $1.1 million, down 53.95% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $991000.0, down from $1.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $4.9 million in Q4 2023, with the low at $959000.0 in Q3 2023.
- The 5-year median for Other Non-Current Liabilities is $2.5 million (2024), against an average of $2.6 million.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities tumbled 73.43% in 2023, then jumped 218.04% in 2024.
- Stoke Therapeutics' Other Non-Current Liabilities stood at $3.0 million in 2022, then jumped by 64.56% to $4.9 million in 2023, then sank by 49.26% to $2.5 million in 2024, then plunged by 53.95% to $1.1 million in 2025, then slipped by 13.15% to $991000.0 in 2026.
- Business Quant data shows STOK's Other Non-Current Liabilities at $991000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 837,000.00 |
| Mar 31, 2026 | 991,000.00 |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.87 Mn |
| Dec 31, 2024 | 2.48 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Mar 31, 2024 | 4.21 Mn |
| Dec 31, 2023 | 4.88 Mn |
| Sep 30, 2023 | 959,000.00 |
| Jun 30, 2023 | 1.63 Mn |
| Mar 31, 2023 | 2.30 Mn |
| Dec 31, 2022 | 2.97 Mn |
| Sep 30, 2022 | 3.61 Mn |
| Jun 30, 2022 | 4.25 Mn |
| Mar 31, 2022 | 3.51 Mn |
| Dec 31, 2021 | 3.95 Mn |